Weight Watchers is Novo Nordisk's latest partnersip.

Among them, WW International (WW), formerly known as WeightWatchers, hit a rough patch earlier this year, resulting in WW ...

Novo Nordisk has bounced back from a sour ending to its Hims & Hers partnership, revealing a new deal with WeightWatchers to expand access to its blockbuster weight loss drug Wegovy (semaglutide). The ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a Strong Buy.

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss drug Wegovy. | Novo Nordisk is partnering with WeightWatchers to offer ...

The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...

The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.

Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...

Novo Nordisk A/S (NYSE:NVO) announced on June 26 that it will collaborate with WeightWatchers to begin distributing the bestselling weight-loss medication Wegovy, beginning July 1.